1 EXECUTIVE SUMMARY
1.1 OVERVIEW 11
1.1.1 MARKET SYNOPSIS 11
2 MARKET INTRODUCTION
2.1 DEFINITION 12
2.2 SCOPE OF THE STUDY 12
2.3 RESEARCH OBJECTIVE 12
2.4 LIST OF ASSUMPTIONS & LIMITATIONS 13
3 RESEARCH METHODOLOGY
3.1 DATA MINING 14
3.2 SECONDARY RESEARCH 15
3.3 PRIMARY RESEARCH 16
3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 16
3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS 17
3.4 FORECASTING TECHNIQUES 18
3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 19
3.5.1 BOTTOM-UP APPROACH 20
3.5.2 TOP-DOWN APPROACH 20
3.6 DATA TRIANGULATION 21
3.7 VALIDATION 21
4 MARKET DYNAMICS
4.1 OVERVIEW 22
4.2 DRIVERS 23
4.2.1 INCREASING PREVALENCE OF CANCER ACROSS THE GLOBE 23
4.2.2 TECHNOLOGICAL ADVANCEMENTS IN THE TREATMENT THERAPIES FOR CANCER 23
4.2.3 GROWING PHARMACEUTICAL INDUSTRY 23
4.2.4 INCREASE IN THE NUMBER OF CLINICAL STUDIES FOR CELL THERAPY 24
4.3 RESTRAINTS 25
4.3.1 SIDE EFFECTS OF CAR T-CELL THERAPY 25
4.3.2 HIGH COST OF TREATMENT 25
4.4 OPPORTUNITY 26
4.4.1 INVESTIGATION ON CAR-T THERAPY FOR THE TREATMENT OF SEVERAL HEMATOLOGIC AND SOLID
TUMOR TYPES 26
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES ANALYSIS 27
5.1.1 THREAT OF NEW ENTRANTS 27
5.1.2 BARGAINING POWER OF SUPPLIERS 28
5.1.3 BARGAINING POWER OF BUYERS 28
5.1.4 THREAT OF SUBSTITUTES 28
5.1.5 INTENSITY OF RIVALRY 28
5.2 CLINICAL TRIALS ANALYSIS 29
5.3 COVID-19 IMPACT ANALYSIS 36
5.3.1 IMPACT ON GDP GROWTH 36
5.3.2 IMPACT ON SUPPLY CHAIN 37
5.3.3 IMPACT ON PRODUCTION 37
5.3.4 IMPACT ON KEY PLAYERS 37
6 GLOBAL CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN
6.1 OVERVIEW 38
6.1.1 CD19 39
6.1.2 CD22 40
6.1.3 OTHERS 40
7 GLOBAL CAR T CELL THERAPY MARKET, BY APPLICATION
7.1 OVERVIEW 41
7.1.1 DIFFUSE LARGE B-CELL LYMPHOMA 43
7.1.2 ACUTE LYMPHOBLASTIC LEUKEMIA 44
7.1.3 OTHERS 44
8 GLOBAL CAR T CELL THERAPY MARKET, BY REGION
8.1 OVERVIEW 45
8.2 US 46
8.3 EUROPE 48
8.4 CHINA 49
8.5 REST OF THE WORLD (ROW) 50
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW 51
9.2 MAJOR PLAYERS IN THE GLOBAL CAR T CELL THERAPY MARKET 51
9.3 COMPETITIVE BENCHMARKING 52
9.4 COMPETITOR DASHBOARD 53
9.5 DEVELOPMENTS IN THE GLOBAL CAR TCELL THERAPY MARKET 53
9.5.1 ACQUISITION 53
9.5.2 JOINT VENTURES 54
9.5.3 EXPANSION 55
9.5.4 REGULATORY APPROVALS 56
9.5.5 IND CLEARANCES 56
9.5.6 PRODUCT LAUNCH/PRODUCT APPROVAL 57
10 COMPANY PROFILES
10.1 NOVARTIS AG 58
10.1.1 COMPANY OVERVIEW 58
10.1.2 FINANCIAL OVERVIEW 58
10.1.3 PRODUCTS/SERVICES OFFERED 59
10.1.4 KEY DEVELOPMENTS 59
10.1.5 SWOT ANALYSIS 60
10.1.6 KEY STRATEGIES 60
10.2 PFIZER, INC. 61
10.2.1 COMPANY OVERVIEW 61
10.2.2 FINANCIAL OVERVIEW 61
10.2.3 PRODUCTS/SERVICES OFFERED 62
10.2.4 KEY DEVELOPMENTS 62
10.2.5 SWOT ANALYSIS 63
10.2.6 KEY STRATEGIES 63
10.3 KITE PHARMA 64
10.3.1 COMPANY OVERVIEW 64
10.3.2 FINANCIAL OVERVIEW 64
10.3.3 PRODUCTS/SERVICES OFFERED 65
10.3.4 KEY DEVELOPMENTS 65
10.3.5 SWOT ANALYSIS 66
10.3.6 KEY STRATEGIES 66
10.4 CELLECTIS 67
10.4.1 COMPANY OVERVIEW 67
10.4.2 FINANCIAL OVERVIEW 67
10.4.3 PRODUCTS/SERVICES OFFERED 68
10.4.4 KEY DEVELOPMENTS 68
10.4.5 SWOT ANALYSIS 69
10.4.6 KEY STRATEGIES 69
10.5 AUTOLUS THERAPEUTICS PLC 70
10.5.1 COMPANY OVERVIEW 70
10.5.2 FINANCIAL OVERVIEW 70
10.5.3 PRODUCTS/SERVICES OFFERED 70
10.5.4 KEY DEVELOPMENTS 71
10.5.5 SWOT ANALYSIS 71
10.5.6 KEY STRATEGIES 71
10.6 CARSGEN THERAPEUTICS 72
10.6.1 COMPANY OVERVIEW 72
10.6.2 FINANCIAL OVERVIEW 72
10.6.3 PRODUCTS/SERVICES OFFERED 72
10.6.4 KEY DEVELOPMENTS 72
10.6.5 SWOT ANALYSIS 73
10.6.6 KEY STRATEGIES 73
10.7 JUNO THERAPEUTICS 74
10.7.1 COMPANY OVERVIEW 74
10.7.2 FINANCIAL OVERVIEW 74
10.7.3 PRODUCTS/SERVICES OFFERED 75
10.7.4 KEY DEVELOPMENTS 75
10.7.5 SWOT ANALYSIS 75
10.7.6 KEY STRATEGIES 76
10.8 SORRENTO THERAPEUTICS, INC. 77
10.8.1 COMPANY OVERVIEW 77
10.8.2 FINANCIAL OVERVIEW 77
10.8.3 PRODUCTS OFFERING 77
10.8.4 KEY DEVELOPMENTS 78
10.8.5 SWOT ANALYSIS 78
10.8.6 KEY STRATEGY 78
10.9 LEGEND BIOTECH 79
10.9.1 COMPANY OVERVIEW 79
10.9.2 FINANCIAL OVERVIEW 79
10.9.3 PRODUCTS/SERVICES OFFERED 80
10.9.4 KEY DEVELOPMENTS 80
10.9.5 SWOT ANALYSIS 81
10.9.6 KEY STRATEGIES 81
10.10 MUSTANG BIO 82
10.10.1 COMPANY OVERVIEW 82
10.10.2 FINANCIAL OVERVIEW 82
10.10.3 PRODUCTS/SERVICES OFFERED 83
10.10.4 KEY DEVELOPMENTS 83
10.10.5 SWOT ANALYSIS 84
10.10.6 KEY STRATEGIES 84
11 APPENDIX
11.1 REFERENCES 85
11.2 RELATED REPORTS 85
12 LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 13
TABLE 2 CLINICAL TRIALS OVERVIEW 29
TABLE 3 KEY COMPANIES AND NUMBER OF CLINICAL TRIALS 36
TABLE 4 GLOBAL CAR T CELL THERAPY MARKET BY TARGET ANTIGEN, 2023-2032 (USD MILLION) 39
TABLE 5 GLOBAL CAR T CELL THERAPY MARKET FOR CD19, BY REGION, 2023-2032 (USD MILLION) 39
TABLE 6 GLOBAL CAR T CELL THERAPY MARKET FOR CD22, BY REGION, 2023-2032 (USD MILLION) 40
TABLE 7 GLOBAL CAR T CELL THERAPY MARKET BY APPLICATION, 2023-2032 (USD MILLION) 42
TABLE 8 GLOBAL CAR T CELL THERAPY MARKET FOR DIFFUSE LARGE B-CELL LYMPHOMA, BY REGION, 2023-2032 (USD MILLION) 43
TABLE 9 GLOBAL CAR T CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2023-2032 (USD MILLION) 44
TABLE 10 GLOBAL CAR T CELL THERAPY MARKET, BY REGION, 2023-2032 (USD MILLION) 46
TABLE 11 US CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2023-2032 (USD MILLION) 46
TABLE 12 US CAR T CELL THERAPY MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 47
TABLE 13 EUROPE CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2023-2032 (USD MILLION) 48
TABLE 14 EUROPE CAR T CELL THERAPY MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 48
TABLE 15 CHINA CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2023-2032 (USD MILLION) 49
TABLE 16 CHINA CAR T CELL THERAPY MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 49
TABLE 17 REST OF THE WORLD (ROW) CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2023-2032 (USD MILLION) 50
TABLE 18 REST OF THE WORLD (ROW) CAR T CELL THERAPY MARKET, BY APPLICATION, 2023-2032 (USD MILLION) 50
TABLE 19 MAJOR PLAYERS IN THE GLOBAL CAR T CELL THERAPY MARKET 51
TABLE 20 COMPETITOR DASHBOARD: GLOBAL CAR T SCELL THERAPY MARKET 53
TABLE 21 ACQUISITION 53
TABLE 22 JOINT VENTURES 54
TABLE 23 EXPANSION 55
TABLE 24 REGULATORY APPROVALS 56
TABLE 25 IND CLEARANCES 56
TABLE 26 PRODUCT LAUNCH/PRODUCT APPROVAL 57
13 LIST OF FIGURES
FIGURE 1 GLOBAL CAR T CELL THERAPY MARKET STRUCTURE 13
FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 19
FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL CAR T-CELL THERAPY MARKET 22
FIGURE 4 DRIVERS: IMPACT ANALYSIS 24
FIGURE 5 RESTRAINTS: IMPACT ANALYSIS 25
FIGURE 6 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL CAR T CELL THERAPY MARKET 27
FIGURE 7 ONGOING CLINICAL TRIAL PHASES (%) 35
FIGURE 8 KEY COMPANIES’ CLINICAL TRIALS, (%) 36
FIGURE 9 GLOBAL CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2023 (%) 38
FIGURE 10 GLOBAL CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2023 & 2032 (USD MILLION) 38
FIGURE 11 GLOBAL CAR T CELL THERAPY MARKET, BY APPLICATION, 2023 (%) 41
FIGURE 12 GLOBAL CAR T CELL THERAPY MARKET, BY APPLICATION, 2023 & 2032 42
FIGURE 13 GLOBAL CAR T CELL THERAPY MARKET, BY REGION, 2023 (%) 45
FIGURE 14 GLOBAL CAR T CELL THERAPY MARKET, BY REGION, 2023 & 2032 (USD MILLION) 45
FIGURE 15 BENCHMARKING OF MAJOR COMPETITORS 52